Catalent is a global leader in in developing and manufacturing oral solid dosage forms. Offering integrated early phase drug development solutions including PBPK modeling, molecule characterization, bioavailability enhancement, API-sparing development techniques and phase-appropriate dose forms, Catalent can help accelerate molecules from candidate to clinic and beyond. With a proven track record in the successful scale-up of manufacturing processes and seamless technology transfers, Catalent leverages expertise and scale across a global network to match the best technologies to optimal oral dose forms to enable successful programs. From early phase development through clinical supply and commercial manufacturing, Catalent is committed to partnering with you to help bring molecules to market faster as optimal treatments for patients.